Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047133 · ClinicalTrials.gov registry record · Phase 2
Effect of Early Administration of TXA in Adult Hip Fractures
A Phase 2 study of Postoperative Blood Loss, sponsored by Ascension Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT05047133: Recruiting Phase 2 study of Postoperative Blood Loss, sponsored by Ascension Health.
NCT05047133 is a Phase 2 study of Postoperative Blood Loss that is actively recruiting participants, run by Ascension Health. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047133, a Phase 2 study of Postoperative Blood Loss, is actively recruiting participants, sponsored by Ascension Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Primary Outcome
Patient receives a blood transfusion during their postoperative stay in the hospital
Conditions Studied
Interventions
- DRUG Tranexamic acid
Study Locations (1)
Michigan
- Ascension Genesys Hospital - Grand Blanc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2022-07-01 |
| Phase | Phase 2 |
What NCT05047133 shows while recruiting
NCT05047133 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Postoperative Blood Loss appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid is the first listed.
NCT05047133 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05047133 about?
NCT05047133 is a clinical study titled "Effect of Early Administration of TXA in Adult Hip Fractures". This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperativ...
What is the current status of trial NCT05047133?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2021-09-01. Estimated completion is 2022-07-01.
What conditions does trial NCT05047133 study?
This clinical trial studies the following conditions: Postoperative Blood Loss.
What interventions are being tested in trial NCT05047133?
The interventions under investigation include: Tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT05047133?
This trial is sponsored by Ascension Health, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05047133 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Blood Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05047133's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI